launch own cryptocurrency Knowledge

Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.It is predicted that the State Council Press Office will hold a press conference at 10 am on Monday, December 16th, 2024, and ask Fu Linghui, spokesperson of the National Bureau of Statistics and head of the National Economic Statistics Department, to introduce the national economic operation in November 2024 and answer questions from reporters.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)

It is predicted that the State Council Press Office will hold a press conference at 10 am on Monday, December 16th, 2024, and ask Fu Linghui, spokesperson of the National Bureau of Statistics and head of the National Economic Statistics Department, to introduce the national economic operation in November 2024 and answer questions from reporters. Hongxin Electronics: Promote the technical research and development and product supply of folding mobile phone reels with Xiaomi. Hongxin Electronics officially announced today that recently, the 2024 Xiaomi Global Core Supplier Conference was held in Beijing Yanqi Lake International Convention & Exhibition Center. Under the background that Xiaomi's strategy of "people, cars and homes are all ecological" continues to deepen, Hongxin Electronics will closely follow Xiaomi's footsteps, actively expand emerging fields such as home appliances and automobiles, and provide all-round support and services in flexible electronics for Xiaomi's intelligent hardware all-ecological products. At present, in the face of the booming folding mobile phone market, Hongxin Electronics and Xiaomi jointly promote the technology research and development and product supply of folding mobile phone reels. According to reports, in the era of vigorous development of artificial intelligence and digital economy, at present, Hongxin Electronics has deeply laid out frontier fields such as AI mobile phones, AIPC, smart cars, smart homes, smart wearable devices, robots, industrial control, medical care and meta-universe.

Shenzhen Longgang Yueke Artificial Intelligence Venture Capital Fund was established with a capital contribution of 1 billion yuan. According to Tianyanchao App, recently, Shenzhen Longgang Yueke Artificial Intelligence Venture Capital Fund Partnership (Limited Partnership) was established. The executive partner is Guangdong Yueke Parent Fund Investment Management Co., Ltd., with a capital contribution of 1 billion yuan. The business scope is to engage in equity investment, investment management, asset management and other activities with private equity funds. Shenzhen Longgang District Guide Fund Investment Co., Ltd. and Guangdong Emerging Industry Investment Fund Partnership.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.On the 13th, the 30-year treasury bond futures rose by 0.60%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the main contract 30-year treasury bond futures closed at 2503, up or down by +0.60%, with a turnover of 71,900 lots. The position data showed that the top 20 seats were clear, and the difference position was 3,777 lots. The total number of 30-year treasury bond futures contracts was 82,700 lots, an increase of 4,416 lots over the previous day. The first 20 seats in the contract held 78,000 lots, a decrease of 1,313 lots from the previous day. The top 20 seats in the contract held 85,000 short positions, a decrease of 1,049 lots from the previous day. (Sina Futures)